Literature DB >> 12823283

Dysregulated expression of IFN-gamma and IL-10 and impaired IFN-gamma-mediated responses at different disease stages in patients with genital herpes simplex virus-2 infection.

R Singh1, A Kumar, W D Creery, M Ruben, A Giulivi, F Diaz-Mitoma.   

Abstract

Cell-mediated T-helper type-1 (Th1) responses play a vital role in the immunopathogenesis of genital infections caused by herpes simplex virus 2 (HSV-2). We investigated the role of Th responses in HSV-2 infection at different disease stages by analysing the production of Th cytokines in HSV-stimulated peripheral blood mononuclear cells (PBMCs). IFN-gamma production decreased over time following a recurrence, whereas levels of IL-10, and to a lesser extent IL-2, remained elevated during this period. In addition, PBMCs from asymptomatic seropositive individuals produced high levels of IFN-gamma and low levels of IL-10, in contrast to individuals with a history of genital ulcers. Following a recurrence, virus copy number in the genital lesions decreased progressively over time, in a manner similar to IFN-gamma production by HSV-2-stimulated PBMCs. Enhanced production of IFN-gamma may modulate HSV replication and B7 expression on monocytic cells of HSV-infected individuals. In contrast to seronegative controls, IFN-gamma failed to enhance B7 expression on monocytic cells of HSV-infected individuals. In addition, monocytic cells from HSV-2-infected individuals with recurrent disease supported greater HSV replication than did those of HSV-infected asymptomatic individuals or seronegative controls. Furthermore, addition of IFN-gamma resulted in enhanced HSV replication in monocytic cells of HSV-infected individuals with recurrent disease, in contrast to the inhibition observed in HSV-seropositive asymptomatic individuals and seronegative controls. Taken together, our results suggest that dysregulated production of IFN-gamma at different disease stages and the impaired ability of monocytic cells to respond to IFN-gamma may play a role in the pathogenesis of recurrent genital herpes disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12823283      PMCID: PMC1808753          DOI: 10.1046/j.1365-2249.2003.02183.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  44 in total

1.  Distinct role of p38 and c-Jun N-terminal kinases in IL-10-dependent and IL-10-independent regulation of the costimulatory molecule B7.2 in lipopolysaccharide-stimulated human monocytic cells.

Authors:  Wilfred Lim; Wei Ma; Katrina Gee; Susan Aucoin; Devki Nandan; Francisco Diaz-Mitoma; Maya Kozlowski; Ashok Kumar
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

2.  The role of natural killer cells and interferon in resistance to acute infection of mice with herpes simplex virus type 1.

Authors:  J F Bukowski; R M Welsh
Journal:  J Immunol       Date:  1986-05-01       Impact factor: 5.422

3.  Nucleotide sequence of the DNA polymerase gene of herpes simplex virus type 2 and comparison with the type 1 counterpart.

Authors:  T Tsurumi; K Maeno; Y Nishiyama
Journal:  Gene       Date:  1987       Impact factor: 3.688

4.  Dysregulation of B7.2 (CD86) expression on monocytes of HIV-infected individuals is associated with altered production of IL-2.

Authors:  A Kumar; J B Angel; S Aucoin; W D Creery; M P Daftarian; D W Cameron; L Filion; F Diaz-Mitoma
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

Review 5.  Biology of human TH1 and TH2 cells.

Authors:  S Romagnani
Journal:  J Clin Immunol       Date:  1995-05       Impact factor: 8.317

6.  Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes.

Authors:  K K Sethi; Y Omata; K E Schneweis
Journal:  J Gen Virol       Date:  1983-02       Impact factor: 3.891

7.  Interleukin-2 protects neonatal mice from lethal herpes simplex virus infection: a macrophage-mediated, gamma interferon-induced mechanism.

Authors:  S Kohl; L S Loo; D B Drath; P Cox
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

8.  Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with interferon-gamma.

Authors:  Z Mikloska; A M Kesson; M E Penfold; A L Cunningham
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

9.  Sequence and mapping analyses of the herpes simplex virus DNA polymerase gene predict a C-terminal substrate binding domain.

Authors:  J S Gibbs; H C Chiou; J D Hall; D W Mount; M J Retondo; S K Weller; D M Coen
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

10.  Characterization of herpes simplex virus type-1 infection and herpetic stromal keratitis development in IFN-gamma knockout mice.

Authors:  D M Bouley; S Kanangat; W Wire; B T Rouse
Journal:  J Immunol       Date:  1995-10-15       Impact factor: 5.422

View more
  13 in total

1.  STAT4 regulates antiviral gamma interferon responses and recurrent disease during herpes simplex virus 2 infection.

Authors:  Alexandra Svensson; Petra Tunbäck; Inger Nordström; Andrey Shestakov; Leonid Padyukov; Kristina Eriksson
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

2.  Inhibition of γ-secretase cleavage in the notch signaling pathway blocks HSV-2-induced type I and type II interferon production.

Authors:  Alexandra Svensson; Emely Jäkärä; Andrey Shestakov; Kristina Eriksson
Journal:  Viral Immunol       Date:  2010-12       Impact factor: 2.257

3.  Griffithsin protects mice from genital herpes by preventing cell-to-cell spread.

Authors:  Briana Nixon; Martha Stefanidou; Pedro M M Mesquita; Esra Fakioglu; Theodore Segarra; Lisa Rohan; William Halford; Kenneth E Palmer; Betsy C Herold
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

4.  Chemokines and Chemokine Receptors Critical to Host Resistance following Genital Herpes Simplex Virus Type 2 (HSV-2) Infection.

Authors:  M Thapa; D J J Carr
Journal:  Open Immunol J       Date:  2008

Review 5.  Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.

Authors:  Jairam R Lingappa; Connie Celum
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Herpes simplex virus type 2 vaccines: new ground for optimism?

Authors:  L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

7.  Herpes simplex virus type 2-induced mortality following genital infection is blocked by anti-tumor necrosis factor alpha antibody in CXCL10-deficient mice.

Authors:  Manoj Thapa; Daniel J J Carr
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

8.  Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B.

Authors:  Aziz Alami Chentoufi; Nicholas R Binder; Noureddine Berka; Guillaume Durand; Alex Nguyen; Ilham Bettahi; Bernard Maillère; Lbachir BenMohamed
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

9.  CXCL9 and CXCL10 expression are critical for control of genital herpes simplex virus type 2 infection through mobilization of HSV-specific CTL and NK cells to the nervous system.

Authors:  Manoj Thapa; Robert S Welner; Rosana Pelayo; Daniel J J Carr
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

Review 10.  [Genital herpes and HSV transmission in HIV patients].

Authors:  H F Rabenau; H W Doerr
Journal:  Hautarzt       Date:  2008-01       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.